Baker Bros. Advisors LP Summit Therapeutics Inc. Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 24,424,865 shares of SMMT stock, worth $540 Million. This represents 4.83% of its overall portfolio holdings.
Number of Shares
24,424,865
Previous 24,424,865
-0.0%
Holding current value
$540 Million
Previous $535 Million
18.49%
% of portfolio
4.83%
Previous 5.73%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Vanguard Group Inc Valley Forge, PA11.7MShares$258 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$175 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$145 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$124 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.2MShares$70.8 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.45B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...